Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
about
Metabolic consequences of modern immunosuppressive agents in solid organ transplantationPersonalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicinePharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationA 3'-UTR Polymorphism in Soluble Epoxide Hydrolase Gene Is Associated with Acute Rejection in Renal Transplant RecipientsConversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients.Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approachPopulation pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.PharmGKB summary: cyclosporine and tacrolimus pathwaysRelationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patientsEarly non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients.Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modellingPharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Dosing equation for tacrolimus using genetic variants and clinical factorsMultigene predictors of tacrolimus exposure in kidney transplant recipients.Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function.The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients.Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.Association of Extrarenal Adverse Effects of Posttransplant Immunosuppression With Sex and ABCB1 Haplotypes.Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughsThe role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortiumCYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part IExternal evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipientsEffects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.Pharmacogenetics may Influence Tacrolimus Daily Dose, but not Urinary Tubular Damage Markers in the Long-Term Period after Renal Transplantation.PharmGKB summary: very important pharmacogene information for CYP3A5.Exposure of cyclosporin A in whole blood, cerebral spinal fluid, and brain extracellular fluid dialysate in adults with traumatic brain injury.Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipientsA Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.Decreased tacrolimus levels after administration of rifampin to a patient with renal transplant.Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patientsPopulation pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.Application of Machine-Learning Models to Predict Tacrolimus Stable Dose in Renal Transplant Recipients.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.
P2860
Q26746936-4407BDDC-C7C8-47CD-BC36-3C2A182A9815Q28082746-5160AD65-BF96-44DB-866C-AAA724DD79C9Q28083875-E728FC24-027E-470F-8E2E-F890809D4B83Q28384776-C6BD6885-CEF0-4189-948F-F6871B2E0796Q30418087-724161D6-E0CD-4C8F-A97E-530D4158FB66Q33574176-9046AF72-A9F7-4CC5-AE58-E82D51C63EC5Q33888004-B58EEF4F-C3AE-4AD6-AF7C-FDF687D39CC5Q33977228-53A91EAB-9465-494E-A39F-3B21F766F8FDQ33989902-C4BF3AAC-7756-49EA-8B0D-2229EF89F431Q34065305-D9C188EF-1934-4678-9879-52B704FAE6B2Q34511457-510019D6-43D0-40BF-B7C5-3C630B3E27DAQ34571036-E0FB1EC6-597F-4CD5-A4BF-09889B1FE1D8Q34680467-742EBCC9-7E55-4814-99AB-AF6E99D24063Q35629782-5F3E5D5C-83CF-4FBC-ADFD-293D1E878E76Q35924246-97F72869-A9F1-42D1-BA67-F15AD747B3CCQ35943046-7DF2F9D1-75AC-49AF-9855-206A5E4DFE53Q36112215-7651631F-B38E-4577-98ED-C790FFB36316Q36125433-F50E5D44-0E8D-4A7D-8EB2-8AED30D9BC10Q36183911-DAA1372F-2CF0-41BD-82A6-F8961A398FA8Q36256056-4F9A498E-6F2D-42E2-BF74-178872CCFC0EQ36442886-10CB8055-CFE9-4F17-8F92-A68ED379E753Q36513703-A1F7B0EE-50F7-42FA-B49E-BBB86E939CB6Q36630081-D26AFCE5-55AC-4DDA-A349-227A18AA5628Q36704223-8B19A56B-9268-4311-BFCF-B1B4620AA9FEQ36777599-FC426945-22BF-4954-A50D-BD2FFC60413BQ36806621-541050D7-3A18-43F9-A8EA-4D373CB94332Q36806652-83C409A0-E758-4ACD-A9ED-293C4E24E783Q37038199-4C48853A-DEAD-4E33-B3A3-BAE6EE417424Q37041351-C6F322DE-E234-4FA8-B91A-8026D226912FQ37081741-1B4594DE-CF85-4CCB-B054-8DA010415D45Q37115083-E8D10C96-73D0-4229-B296-284A5A36269EQ37126092-02B685C5-B25E-4E8A-A777-BDC76A71760EQ37207789-B5DCCC5E-8D57-41F8-B9F3-958673C011DDQ37402295-8F1D8174-FDA3-4A03-99DC-F6730B2D9549Q37439873-D4B9CD02-CA07-4366-9C23-B7B080D836C8Q37492036-ED420221-35E9-408F-BB3F-082CD2018F18Q37620393-7D13B005-3F63-49C6-A7F6-424A4D85FBA1Q37630718-83257D3E-4716-40A1-B777-28EE6619527FQ37678060-9BF4C77C-5E68-46BA-B018-CBB0A3B82A30Q37727173-432B937C-53BE-4950-B3DB-2A6B28AE12F1
P2860
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@ast
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@en
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@nl
type
label
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@ast
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@en
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@nl
prefLabel
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@ast
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@en
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@nl
P1476
Effect of CYP3A and ABCB1 sing ...... alcineurin inhibitors: Part I.
@en
P2093
Susan E Tett
P304
P356
10.2165/11317350-000000000-00000
P577
2010-03-01T00:00:00Z
P6179
1037737386